Abstract
Cryptococcosis is a fungal disease of global significance for which new effective treatments are needed. The conjugation of the synthetic antimicrobial peptide fragment UBI 31-38 to a coumarin derivative showed to be an effective approach for the design of a novel anticryptococcal agent. In addition to antifungal activity, the conjugate exhibited intense fluorescence, which could be valuable for mechanistic investigations of this molecule. In this work, we studied the photophysical properties of the conjugate and confocal scanning laser microscopy was used to inspect the distribution of the peptide-coumarin conjugate in Cryptococcus cell. The synergism of this compound with amphotericin B or fluconazole against C. gattii and C. neoformans strains was also investigated. The results indicated that the fluorescent conjugate alone as well as its combination with amphotericin B are promising tools against cryptococcosis.
Keywords: UBI 31-38, peptide-coumarin conjugate, fluorescent, anticryptococcal activity, interaction studies, confocal scanning laser microscopy.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:A UBI 31-38 Peptide-coumarin Conjugate: Photophysical Features, Imaging Tracking and Synergism with Amphotericin B Against Cryptococcus
Volume: 18 Issue: 2
Author(s): Soraya M.Z.M.D. Ferreira, Hellem C. Carneiro, Rosemeire B. Alves, Ana Carolina S. Batista, Eufranio N. da Silva Junior, Gleiston G. Dias, Jarbas M. Resende, Daniel A. Santos, Debora L. Oliveira, Marcio L. Rodrigues and Rossimiriam P. Freitas*
Affiliation:
- Departamento de Quimica, Instituto de Ciencias Exatas, Universidade Federal de Minas Gerais, Belo Horizonte,Brazil
Keywords: UBI 31-38, peptide-coumarin conjugate, fluorescent, anticryptococcal activity, interaction studies, confocal scanning laser microscopy.
Abstract: Cryptococcosis is a fungal disease of global significance for which new effective treatments are needed. The conjugation of the synthetic antimicrobial peptide fragment UBI 31-38 to a coumarin derivative showed to be an effective approach for the design of a novel anticryptococcal agent. In addition to antifungal activity, the conjugate exhibited intense fluorescence, which could be valuable for mechanistic investigations of this molecule. In this work, we studied the photophysical properties of the conjugate and confocal scanning laser microscopy was used to inspect the distribution of the peptide-coumarin conjugate in Cryptococcus cell. The synergism of this compound with amphotericin B or fluconazole against C. gattii and C. neoformans strains was also investigated. The results indicated that the fluorescent conjugate alone as well as its combination with amphotericin B are promising tools against cryptococcosis.
Export Options
About this article
Cite this article as:
Ferreira M.Z.M.D. Soraya , Carneiro C. Hellem , Alves B. Rosemeire, Batista Carolina S. Ana , da Silva Junior N. Eufranio , Dias G. Gleiston , Resende M. Jarbas , Santos A. Daniel , Oliveira L. Debora , Rodrigues L. Marcio and Freitas P. Rossimiriam*, A UBI 31-38 Peptide-coumarin Conjugate: Photophysical Features, Imaging Tracking and Synergism with Amphotericin B Against Cryptococcus, Current Topics in Medicinal Chemistry 2018; 18 (2) . https://dx.doi.org/10.2174/1568026618666180221113137
DOI https://dx.doi.org/10.2174/1568026618666180221113137 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Current Alzheimer Research Humanized Mouse Models of HIV-1 Latency
Current HIV Research Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Impact of Latent Viral Infections in Mechanically Ventilated Patients
Current Respiratory Medicine Reviews Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Letters in Drug Design & Discovery Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Copper as a Biocidal Tool
Current Medicinal Chemistry Therapeutic Perspectives in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Impact of the CD40-CD40L Dyad in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry New Proposals for Treatment Sporadic Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets